Repros Receives FDA Guidance Regarding Clinical Program for Androxal

Loading...
Loading...
Repros Therapeutics
RPRX
today reported it has received guidance from the FDA regarding its clinical program for Androxal. The Company had previously submitted a list of questions with the final clinical study report for ZA-301. Repros subsequently provided an update of topline results from ZA-302 to the FDA. The primary purpose of the requested teleconference is to determine if Site 9 (men referred from a fertility clinic) should be included in the final analysis of Study ZA-301. Study ZA-301 was not originally powered to allow for exclusion of Site 9 from the calculation of non-inferiority versus placebo for drops in sperm counts. However, Study ZA-302 was powered for analysis with or without Site 9 and met the co-primary
See full press release
Posted In: NewsGuidanceOfferingsContractsFDAManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...